Dyne Therapeutics (DYN)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Dyne Therapeutics (DYN)
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Key Insights
Critical company metrics and information
Share Price
$29.44Market Cap
$3.00 BillionTotal Outstanding Shares
101.77 Million SharesTotal Employees
173Dividend
No dividendIPO Date
September 17, 2020SIC Description
Pharmaceutical PreparationsHomepage
https://www.dyne-tx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-243.04 Million |
| Net Cash Flow | $401.50 Million |
| Net Cash Flow, Continuing | $401.50 Million |
| Net Cash Flow From Investing Activities | $-161.87 Million |
| Net Cash Flow From Investing Activities, Continuing | $-161.87 Million |
| Net Cash Flow From Financing Activities, Continuing | $806.41 Million |
| Net Cash Flow From Financing Activities | $806.41 Million |
| Net Cash Flow From Operating Activities, Continuing | $-243.04 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Available To Common Stockholders, Basic | $-294.51 Million |
| Diluted Earnings Per Share | $3.56 |
| Net Income/Loss Attributable To Parent | $-294.51 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Revenues | $0.00 |
| Net Income/Loss | $-294.51 Million |
| Income/Loss From Continuing Operations Before Tax | $-294.51 Million |
| Research and Development | $258.45 Million |
| Operating Income/Loss | $-314.47 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Operating Expenses | $314.47 Million |
| Basic Earnings Per Share | $3.56 |
| Other Operating Expenses | $56.02 Million |
| Income/Loss From Continuing Operations After Tax | $-294.51 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $768.84 Million |
| Other Current Liabilities | $25.79 Million |
| Noncurrent Liabilities | $20.04 Million |
| Assets | $768.84 Million |
| Fixed Assets | $4.90 Million |
| Current Assets | $736.39 Million |
| Accounts Payable | $6.16 Million |
| Noncurrent Assets | $32.45 Million |
| Current Liabilities | $43.26 Million |
| Equity Attributable To Parent | $705.54 Million |
| Wages | $11.31 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Other Non-current Assets | $27.56 Million |
| Equity | $705.54 Million |
| Liabilities | $63.30 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.